Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)

• Status: Recruiting
• Trial end date: 2022-03-31
• Target enrollment: 0
• Participant gender: All

Summary

Prospective observational study to IDEntify patients with advanced/metastatic NSCLC and ALK and ROS1 translocation and to establish their therapeutic management (IDEALK&ROS)

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Crizotinib

Criteria

Inclusion Criteria:

• Patients with Advanced or metastatic non-small cell lung cancer

• Patients who will be screened for anaplastic lymphoma kinase (ALK) rearrangement

• Age > 18 years

• For the patients that will be recruited prospectively: Patients must have a signed informed consent document.

• For the treatment sub-study, patients must also meet the following criteria

• Confirmed anaplastic lymphoma kinase (ALK)-positive tumour

• Patients treated with crizotinib under routine clinical practice

• Patients with a minimum data registered at the medical history

For the ROS1 treatment sub-study:

• Confirmation of NSCLC with ROS1-positive translocation

• Have been eligible to receive treatment with crizotinib according to routine clinical practice since the market launch of the ROS1 indication in Spain on 8 February 2017 until the opening of the site.

• Patients should have a predetermined minimum amount of data recorded in their medical records.

Exclusion Criteria:

• Any patient who does not meet any of the inclusion criteria defined in the previous section, depending on the sub-study for which they are included.